Exanthema Market Projected to Offer Substantial Growth Opportunities, Reaching $2.65 Billion by 2029
Grab 20% Off With Code ONLINE20 On Global market Reports – Evaluate Global Trends, Market Risks, and Competitive Intelligence
What Is the Comparative Market Size of the Exanthema Market Between 2025 and 2029?
The exanthema market size has grown steadily in recent years. It will grow from $2.18 billion in 2024 to $2.26 billion in 2025 at a compound annual growth rate (CAGR) of 3.6%. The growth in the historic period can be attributed to increasing healthcare expenditure, increasing awareness regarding vaccination, rising disposable income, increasing awareness of skin disorders, and increasing emphasis on early detection.
The exanthema market size is expected to see steady growth in the next few years. It will grow to " $2.65 billion in 2029 at a compound annual growth rate (CAGR) of 4.1%. The growth in the forecast period can be attributed to rising investments in research and development, increasing prevalence of viral and bacterial infections, growing focus on telemedicine, increasing government initiatives, and rising demand for oral drugs. Major trends in the forecast period include advancements in treatment modalities, innovations in diagnostic methods, technological advancements, advancements in medical research and technology, and assistive technologies.
Get your free report sample today:
What Are the Underlying Growth Drivers for the Exanthema Market?
The rising prevalence of viral infections is expected to propel the growth of the exanthema market going forward. Viral infections refer to illnesses caused by viruses that invade and multiply within the body's cells, leading to various symptoms and diseases. Viral infections are rising due to increasing global travel, urbanization, climate change, and weakened immunity in populations. Rising viral infections drive the demand for exanthema treatments as more cases present with skin rashes, increasing the need for effective management. Exanthema serves as a visible immune response to viral infections, helping to expel pathogens, signal immune activation, and aid in diagnosis by indicating the body's fight against the virus. For instance, in August 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, in 2022–2024, the proportion of individuals with IgM antibodies, indicating a recent Parvovirus B19 infection, remained below 3% but surged to 10% by June 2024. The most significant rise was observed in children aged 5–9 years, where prevalence increased from 15% to 40% during this period. Therefore, the rising prevalence of viral infections is driving the growth of the exanthema market.
What Are the Major Segments Defining the Structure of the Exanthema Market?
The exanthemamarket covered in this report is segmented –
1) By Types: Bacterial; Viral; Other Types
2) By Treatment: Topical Treatments; Systemic Treatments; Supportive Care
3) By Diagnosis Method: Clinical Examination; Laboratory Tests; Imaging Techniques
4) By Application: Rubeola; Rubella; Erythema Infectiosum; Roseola Infantum
5) By End-Users: Hospitals; Homecare; Specialty Centers; Other End-Users
Subsegments:
1) By Bacterial Exanthema: Scarlet Fever; Meningococcemia; Staphylococcal Scalded Skin Syndrome (SSSS); Lyme Disease; Tuberculosis-Associated Exanthema
2) By Viral Exanthema: Measles (Rubeola); Rubella (German Measles); Varicella (Chickenpox); Roseola (Exanthem Subitum); Hand, Foot, and Mouth Disease; Parvovirus B19 (Erythema Infectiosum / Fifth Disease); Dengue Fever Rash; Zika Virus Rash
3) By Other Types of Exanthema: Drug-Induced Exanthema (Hypersensitivity Reactions); Autoimmune-Related Exanthema (Lupus, Kawasaki Disease); Allergic Dermatitis-Related Exanthema; Fungal Infections Leading to Exanthema; Environmental and Toxin-Induced Exanthema
What Are the Key Industry Trends Driving Growth in the Exanthema Market?
Major companies operating in the exanthema market are focusing on developing novel therapeutics, such as the intramuscular (IM) administration of vaccines and antiviral treatments, to improve efficacy, reduce complications, and enhance patient outcomes in managing viral infections associated with exanthematous diseases. Intramuscular (IM) administration of vaccines and antiviral treatments refers to the delivery of medications or vaccines directly into the muscle tissue using a syringe and needle. This method ensures that the substances are absorbed quickly into the bloodstream, leveraging the rich blood supply in the muscles to prompt an immune response or therapeutic effect. For instance, in March 2023, Merck & Co. Inc., a US-based pharmaceutical company, announced that the FDA has approved the intramuscular (IM) administration route for its MMRV vaccines—M-M-R II, VARIVAX, and ProQuad. The IM route is known to offer greater stability and efficacy for these live-virus vaccines compared to other administration methods, making it a crucial step in enhancing public health efforts in preventing these potentially severe viral infections.
Which Firms Represent the Competitive Benchmark Within the Exanthema Market?
Major companies operating in the exanthema market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi SA, Abbott Laboratories, GlaxoSmithKline plc, Serum Institute of India Pvt. Ltd., Takeda Pharmaceutical Company Limited, Amgen Inc., Daiichi Sankyo Company Limited, Biological E. Limited, Zydus Lifesciences Limited, Bio Farma, Meridian Bioscience Inc., West-Ward Pharmaceutical Corp., Trinity Biotech plc, Biosynth Srl, Creative Diagnostics, Taj Pharmaceuticals Limited, TestLine Clinical Diagnostics s.r.o., The Native Antigen Co. Ltd., QED Bioscience Inc.
Get the detailed exanthema market report today
Which Regions Are Driving the Highest Demand in the Exanthema Market?
North America was the largest region in the exanthema market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the exanthema market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment